Search Result
Results for "
uric acid,hypoxanthine
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
6
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B2130R
-
|
Reference Standards
Reactive Oxygen Species (ROS)
Endogenous Metabolite
|
Inflammation/Immunology
|
Uric acid (Standard) is the analytical standard of Uric acid. This product is intended for research and analytical applications. Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .
|
-
-
- HY-B2130
-
-
-
- HY-B2130S1
-
|
Endogenous Metabolite
Reactive Oxygen Species (ROS)
|
Inflammation/Immunology
|
Uric acid- 15N2 is the 15N labeled Uric acid . Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .
|
-
-
- HY-B2130A
-
-
-
- HY-B2130S
-
|
Reactive Oxygen Species (ROS)
Endogenous Metabolite
|
Inflammation/Immunology
|
Uric acid- 13C, 15N3 is the 13C-labeled and 15N-labeled Uric acid. Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .
|
-
-
- HY-W506071
-
-
-
- HY-W780166
-
|
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
|
Uric acid- 13C is the 13C-labeled Uric acid (HY-B2130). Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .
|
-
-
- HY-W770183
-
|
Isotope-Labeled Compounds
|
Others
|
Uric acid- 13C3 is 13C-labeled Uric acid (HY-B2130). Uric acid is the end product of purine metabolism in the human body. Uric acid can scavenge reactive oxygen species (ROS), such as singlet oxygen and peroxynitrite, and inhibit lipid peroxidation.
|
-
-
- HY-B2130S2
-
-
-
- HY-W011711R
-
Fragivix (Standard)
|
Reference Standards
URAT1
|
Metabolic Disease
|
Benzarone (Standard) is the analytical standard of Benzarone. This product is intended for research and analytical applications. Benzarone (Fragivix) is a potent human uric acid transporter 1 (hURAT1) inhibitor, with an IC50 of 2.8 μM in oocyte. Benzarone could lower uric acid serum levels .
|
-
-
- HY-P2921B
-
Uox, Arthrobacter globiformis
|
Endogenous Metabolite
|
Metabolic Disease
|
Uricase, Arthrobacter globiformis is a peroxidase enzyme. It catalyzes the oxidation of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. A deficiency of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .
|
-
-
- HY-P2921A
-
Uox, Bacillus fastidious
|
Endogenous Metabolite
|
Metabolic Disease
|
Uricase, Arthrobacter globiformis is a peroxidase enzyme responsible for catalyzing the oxidative reaction of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. The lack of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .
|
-
-
- HY-P2921C
-
Uox (Recombinant)
|
Endogenous Metabolite
|
Metabolic Disease
|
Uricase, Arthrobacter globiformis is a peroxidase enzyme responsible for catalyzing the oxidative reaction of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. The lack of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .
|
-
-
- HY-B1514
-
-
-
- HY-15933
-
|
Biochemical Assay Reagents
|
Others
Metabolic Disease
|
TOPS is a chromogenic substrate. TOPS undergoes an oxidative coupling reaction with 4-aminoantipyrine in the presence of H2O2 and nanocrystalline cobalt selenide. TOPS is used in studies related to uric acid detection .
|
-
-
- HY-P2755
-
-
-
- HY-P2755A
-
-
-
- HY-P2921
-
Uox
|
Endogenous Metabolite
|
Others
|
Urate oxidase, Microorganism (Uox), i.e., uricase, is often used in biochemical studies. Urate oxidase is a peroxisomal enzyme that catalyzes the oxidation of uric acid to allantoin in most mammals .
|
-
-
- HY-153972
-
|
URAT1
Xanthine Oxidase
|
Metabolic Disease
Inflammation/Immunology
|
URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and URAT1, with IC50 of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a Ki value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia .
|
-
-
- HY-W011711
-
Fragivix
|
URAT1
Oxidative Phosphorylation
Apoptosis
|
Metabolic Disease
|
Benzarone (Fragivix) is an oral inhibitor of human urate transporter 1 (hURAT1) with an IC50 value of 2.8 μM, and it also acts as an uncoupler of oxidative phosphorylation. Benzarone can cause liver damage and promote cell apoptosis and necrosis. Benzarone can be used to lower serum uric acid levels and for research in vascular diseases .
|
-
-
- HY-146273
-
|
Xanthine Oxidase
|
Metabolic Disease
|
Xanthine oxidase-IN-7 (compound1h) is a potent andorally active XO (xanthine oxidase) inhibitor with an IC50 of 0.36 µM. Xanthine oxidase-IN-7 effectively reduces serum uric acid levels. Xanthine oxidase-IN-7 has the potential for the research of hyperuricemia and gout .
|
-
-
- HY-108844
-
|
Xanthine Oxidase
|
Metabolic Disease
Cancer
|
Rasburicase is a recombinant form of urate oxidase that works by catalyzing the oxidation of uric acid to allantoin, which has a higher solubility. Rasburicase specifically degrades uric acid, rapidly lowers blood uric acid levels, and improves inflammation and kidney damage caused by uric acid crystal deposition. Rasburicase can effectively lower uric acid and prevent uric acid nephropathy, and is used in the study of severe hyperuricemia associated with tumor lysis syndrome (TLS) and refractory gout .
|
-
-
- HY-P2921D
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Uricase, candida utilis is a peroxidase enzyme. It catalyzes the oxidation of uric acid, converting it into the soluble product allantoin. Uricase, candida utilis can be used for the determination of uric acid levels in serum. A deficiency of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, candida utilis can be utilized in research on gout and hyperuricemia .
|
-
-
- HY-172778
-
|
NOD-like Receptor (NLR)
URAT1
|
Metabolic Disease
Inflammation/Immunology
|
HNW005 is a dual inhibitor of NLRP3 inflammasome and urate transporter 1 (URAT1). It has a KD value of 204.6 nM and an IC50 of 1.7 μM for inhibiting NLRP3 inflammasome activation, and an IC50 of 6.4 μM for inhibiting uric acid transmembrane transport. When administered at a dose of 2 mg/kg in vivo, HNW005 can achieve a uric acid reduction rate of 64.8%. It can exert anti - inflammatory, analgesic, and uric acid - lowering activities by inhibiting the activation of NLRP3 inflammasome and uric acid transmembrane transport. HNW005 can be used in the research of gouty arthritis .
|
-
-
- HY-173231
-
|
URAT1
|
Metabolic Disease
|
hURAT1 inhibitor 2 (Compound 5) is an inhibitor of hURAT1 (uric acid transporter 1, SLC22A12) with an IC50 of 18 nM. hURAT1 inhibitor 2 also has a certain inhibitory effect on OATP1B1, with an IC50 value of 0.73 μM. hURAT1 inhibitor 2 can be used in the research of diseases related to abnormal uric acid metabolism, such as hyperuricemia and gout .
|
-
-
- HY-161523
-
|
Xanthine Oxidase
URAT1
|
Metabolic Disease
|
XOR/URAT1-IN-1 (Compound II15) is a dual inhibitor for xanthine oxidoreductase (XOR) and uric acid transporter 1 (URAT1), with IC50 of 6 nM and 12.9 μM. XOR/URAT1-IN-1 lowers the levels of uric acid in Potassium oxonate (HY-17511)/Hypoxanthine (HY-N0091)-induced acute hyperuricemia mouse model .
|
-
-
- HY-W011258
-
L-Tyrosyl-L-phenylalanine
|
Xanthine Oxidase
Angiotensin-converting Enzyme (ACE)
|
Inflammation/Immunology
Cancer
|
H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) is an orally active inhibitor of Angiotensin converting enzyme (ACE), with an inhibiton rate of 48% at 50 μM. H-Tyr-Phe-OH can be used as an biomarker for differentiating benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH exhibits xanthine oxidase inhibition (uric acid lowering) activity and serves as regulator in IL-8 production in neutrophil-like cells .
|
-
-
- HY-114309
-
|
URAT1
|
Inflammation/Immunology
|
URAT1 inhibitor 1 (1g) is a uric acid transporter 1 (URAT1) inhibitor, with an IC50 of 32 nM. URAT1 inhibitor 1 has potential to treat hyperuricemia associated with gout .
|
-
-
- HY-W017386
-
|
Endogenous Metabolite
|
Metabolic Disease
|
3-Methyl-2-oxovaleric acid sodium is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid sodium is a biomarker of mustard airway diseases (MADs) and uric acid stone .
|
-
-
- HY-113063
-
|
Endogenous Metabolite
|
Metabolic Disease
|
3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone .
|
-
-
- HY-W721656
-
|
Drug Derivative
|
Inflammation/Immunology
|
Triclacetamol is the trichloroacetyl derivative of Acetaminophen (HY-66005), exhibiting weak cyclooxygenase inhibition and possessing analgesic and antipyretic activities as a nonsteroidal anti-inflammatory drug (NSAID). Triclacetamol acts as an anti-inflammatory agent and promotes the excretion of uric acid .
|
-
-
- HY-W001542
-
-
-
- HY-176139
-
|
URAT1
|
Inflammation/Immunology
|
URAT1 inhibitor 13 (compound 22k) is a potent URAT1 inhibitor. URAT1 inhibitor 13 can be used in the study of gout .
|
-
-
- HY-N10433
-
Icarisids E
|
Xanthine Oxidase
|
Metabolic Disease
|
Xanthine oxidase-IN-9 (Icarisids E) (Compound 2) is a potent xanthine oxidase (XOD) inhibitor with an IC50 of 31.81 μM .
|
-
-
- HY-B1514R
-
|
Reference Standards
Endogenous Metabolite
|
Others
|
Anagrelide (hydrochloride) (Standard) is the analytical standard of Anagrelide (hydrochloride). This product is intended for research and analytical applications. Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action .
|
-
-
- HY-168740
-
|
URAT1
|
Metabolic Disease
|
URAT1 inhibitor 11 (Compound 7) is a URAT1 inhibitor with an IC50 value of 0.18 μM. URAT1 inhibitor 11 exhibits potent hypouricemic effects in hyperuricemic zebrafish induced by Potassium oxonate (HY-17511) and Xanthine sodium salt (HY-W017389) .
|
-
-
- HY-139585
-
LC350189
|
Xanthine Oxidase
|
Metabolic Disease
|
Tigulixostat (LC350189) is an orally active non-purine selective xanthine oxidase inhibitor. Tigulixostat has IC50 values of 0.003 µM and 0.073 µM in bovine milk and rat plasma, respectively. Tigulixostat can effectively reduce serum uric acid levels and can be used in the research of gout and hyperuricemia .
|
-
-
- HY-162882
-
|
Xanthine Oxidase
Reactive Oxygen Species (ROS)
|
Metabolic Disease
|
CC15009 is a xanthine oxidoreductase (XOR) inhibitor, with an IC50 value of 0.237 nM. CC15009 can inhibit the oxidative subtype of XOR, thereby reducing the production of the byproduct ROS and exhibiting antioxidant activity. CC15009 has demonstrated a good dose-dependent uric acid-lowering effect in two different mouse models of hyperuricemia induced by XOR substrates .
|
-
-
- HY-119596
-
|
Xanthine Oxidase
|
Others
|
Eupatoriochromene is a chromene and has inhibitory activity against xanthine oxidase (XO) .
|
-
-
- HY-152033
-
|
URAT1
GLUT
|
Metabolic Disease
|
URAT1 inhibitor 4, a Lesinurad derivative, is a potent and orally active URAT1 inhibitor with an IC50 of 7.56 μM. URAT1 inhibitor 4 has higher in vivo urate-lowering efficacy than Lesinurad (HY-15258) .
|
-
-
- HY-W017386S
-
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
3-Methyl-2-oxovaleric acid-d8 sodium is the deuterium labeled 3-Methyl-2-oxovaleric acid. 3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone .
|
-
-
- HY-113063R
-
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
|
3-Methyl-2-oxovaleric acid (Standard) is the analytical standard of 3-Methyl-2-oxovaleric acid (HY-113063). This product is intended for research and analytical applications. 3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone.
|
-
-
- HY-159718
-
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
NLRP3-IN-46 (Compound 3k) activates neuro-immunomodulatory cholinergic anti-inflammatory pathway, and thus inhibits NLRP3 inflammasome activation. NLRP3-IN-46 inhibits Uric acid sodium (HY-B2130A)-induced IL-1β production in THP-1 cells, and can be used in gouty arthritis research .
|
-
-
- HY-P10218A
-
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
-
- HY-P10218
-
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
-
- HY-W017389R
-
|
Reference Standards
Endogenous Metabolite
|
Inflammation/Immunology
|
Xanthine (Standard) is the analytical standard of Xanthine. This product is intended for research and analytical applications. Xanthine, a plant alkaloid found in tea, coffee, and cocoa, is a mild stimulant of the central nervous system. Xanthine also acts as an intermediate product on the pathway of purine degradation .
In Vitro: A number of stimulants are derived from Xanthine including caffeine and theobromine. Xanthine is a product on the pathway of purine degradation. Xanthine is subsequently converted to uric acid by the action of the Xanthine oxidase enzyme.
|
-
-
- HY-P10876
-
|
Amyloid-β
|
Neurological Disease
|
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
|
-
-
- HY-14874
-
FYX-051
|
Xanthine Oxidase
Cytochrome P450
|
Metabolic Disease
|
Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment .
|
-
-
- HY-14874R
-
FYX-051 (Standard)
|
Reference Standards
Xanthine Oxidase
Cytochrome P450
|
Metabolic Disease
|
Topiroxostat (Standard) is the analytical standard of Topiroxostat. This product is intended for research and analytical applications. Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment .
|
-
-
- HY-158056
-
|
GLUT
URAT1
|
Metabolic Disease
|
URAT1/GLUT9-IN-1 (compound 29) can inhibit both uric acid transporter 1 (URAT1) (IC50=2.01 μM) and glucose transporter 9 (GLUT9) (IC50=18.21 μM). URAT1/GLUT9-IN-1 exhibits favorable pharmacokinetic properties and oral bioavailability. URAT1/GLUT9-IN-1 can be uesd for gout and hyperuricemia research .
|
-
- HY-162829
-
|
URAT1
GLUT
|
Metabolic Disease
|
hURAT1 inhibitor 1 (compound 27b) is an isomarine-based, orally active dual hURAT1/GLUT9 inhibitor with IC50s of 0.16 μM and 4.47 μM, respectively, and has anti-hyperuricemia effects. hURAT1 inhibitor 1 showed significant uric acid-lowering activity in a hyperuricemia mouse model (10 mg/kg dose). hURAT1 inhibitor 1 had no significant in vitro cytotoxicity or in vivo hepatotoxicity and showed good PK characteristics .
|
-
- HY-P10318
-
|
GLP Receptor
|
Endocrinology
|
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
|
-
- HY-P10869
-
|
Natriuretic Peptide Receptor (NPR)
|
Inflammation/Immunology
Cancer
|
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .
|
-
- HY-P10200
-
|
Bacterial
|
Infection
|
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
|
-
- HY-P0041A
-
-
- HY-P0041
-
-
- HY-P3462A
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
- HY-P5161
-
-
- HY-P5161A
-
-
- HY-P3462
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
- HY-14998
-
MK 185
|
β-catenin
PPAR
Wnt
|
Endocrinology
|
Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo .
|
-
- HY-P10271
-
|
GLP Receptor
|
Metabolic Disease
|
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
|
-
- HY-P10341
-
|
GCGR
|
Metabolic Disease
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
-
- HY-P3143
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-P3143A
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-143906
-
|
URAT1
|
Inflammation/Immunology
|
URAT1 inhibitor 2 is an orally active and potent URAT1 and CYP isozyme inhibitor, with IC50 values of 1.36 μM, 16.97 μM, 5.22 μM for URAT1-mediated 14C-UA uptake, CYP1A2 and CYP2C9, respectively. URAT1 inhibitor 2 is a promising agent candidate in the study of hyperuricemia and gout .
|
-
- HY-113560
-
-
- HY-P4146
-
BI 456906
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P4146A
-
BI 456906 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P1162
-
-
- HY-P10031A
-
|
GLP Receptor
GCGR
|
Metabolic Disease
|
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors.?SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .
|
-
- HY-P10031
-
|
GLP Receptor
GCGR
|
Metabolic Disease
|
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .
|
-
- HY-P10272
-
PTG-300
|
Ferroportin
|
Others
|
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
|
-
- HY-P4895
-
|
Oxytocin Receptor
|
Neurological Disease
|
(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .
|
-
- HY-P10881
-
-
- HY-P10563
-
BHV-1100
|
CD38
|
Cancer
|
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-15933
-
|
Indicators
|
TOPS is a chromogenic substrate. TOPS undergoes an oxidative coupling reaction with 4-aminoantipyrine in the presence of H2O2 and nanocrystalline cobalt selenide. TOPS is used in studies related to uric acid detection .
|
-
- HY-W017386
-
|
Enzyme Substrates
|
3-Methyl-2-oxovaleric acid sodium is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid sodium is a biomarker of mustard airway diseases (MADs) and uric acid stone .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-W011258
-
L-Tyrosyl-L-phenylalanine
|
Xanthine Oxidase
Angiotensin-converting Enzyme (ACE)
|
Inflammation/Immunology
Cancer
|
H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) is an orally active inhibitor of Angiotensin converting enzyme (ACE), with an inhibiton rate of 48% at 50 μM. H-Tyr-Phe-OH can be used as an biomarker for differentiating benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH exhibits xanthine oxidase inhibition (uric acid lowering) activity and serves as regulator in IL-8 production in neutrophil-like cells .
|
-
- HY-P10218A
-
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
- HY-P10218
-
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
- HY-P10869
-
|
Natriuretic Peptide Receptor (NPR)
|
Inflammation/Immunology
Cancer
|
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .
|
-
- HY-P0041A
-
-
- HY-P10876
-
|
Amyloid-β
|
Neurological Disease
|
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
|
-
- HY-P10318
-
|
GLP Receptor
|
Endocrinology
|
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
|
-
- HY-P4837
-
|
Peptides
|
Others
|
Ac-Lys-D-Ala-D-lactic acid is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
-
- HY-P10200
-
|
Bacterial
|
Infection
|
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
|
-
- HY-P0041
-
-
- HY-P3462A
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
- HY-P5161
-
-
- HY-P5161A
-
-
- HY-P3462
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
- HY-P10271
-
|
GLP Receptor
|
Metabolic Disease
|
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
|
-
- HY-P10341
-
|
GCGR
|
Metabolic Disease
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
-
- HY-P3143
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-P3143A
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-113560
-
-
- HY-P10381
-
|
Peptides
|
Others
|
palm11-TTDS-PrRP31 is a strong agonist of GPR10 (EC50: 84 pM). palm11-TTDS-PrRP31 has long-lasting anorexigenic effects .
|
-
- HY-P4146
-
BI 456906
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P4146A
-
BI 456906 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P1162
-
-
- HY-P2595
-
|
Peptides
|
Cardiovascular Disease
|
SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .
|
-
- HY-P10031A
-
|
GLP Receptor
GCGR
|
Metabolic Disease
|
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors.?SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .
|
-
- HY-P10031
-
|
GLP Receptor
GCGR
|
Metabolic Disease
|
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .
|
-
- HY-P10272
-
PTG-300
|
Ferroportin
|
Others
|
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
|
-
- HY-P4895
-
|
Oxytocin Receptor
|
Neurological Disease
|
(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .
|
-
- HY-P10881
-
-
- HY-P10563
-
BHV-1100
|
CD38
|
Cancer
|
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B2130S1
-
|
Uric acid- 15N2 is the 15N labeled Uric acid . Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .
|
-
-
- HY-B2130S
-
|
Uric acid- 13C, 15N3 is the 13C-labeled and 15N-labeled Uric acid. Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .
|
-
-
- HY-W017386S
-
|
3-Methyl-2-oxovaleric acid-d8 sodium is the deuterium labeled 3-Methyl-2-oxovaleric acid. 3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone .
|
-
-
- HY-W780166
-
|
Uric acid- 13C is the 13C-labeled Uric acid (HY-B2130). Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .
|
-
-
- HY-W770183
-
|
Uric acid- 13C3 is 13C-labeled Uric acid (HY-B2130). Uric acid is the end product of purine metabolism in the human body. Uric acid can scavenge reactive oxygen species (ROS), such as singlet oxygen and peroxynitrite, and inhibit lipid peroxidation.
|
-
-
- HY-B2130S2
-
|
Uric acid- 13C5 is the 13C-labeled Uric acid (HY-B2130). Radioactive isotopes labeled compounds can be used in metabolic analysis, allowing the movement of individual atoms to be precisely tracked and quantified .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: